Total and Active Rabbit Antithymocyte Globulin (rATG;Thymoglobulin®) Pharmacokinetics in Pediatric Patients Undergoing Unrelated Donor Bone Marrow Transplantation  by Call, Sandra K. et al.
Total and Active Rabbit Antithymocyte Globulin
(rATG;Thymoglobulin) Pharmacokinetics in Pediatric
Patients Undergoing Unrelated Donor Bone Marrow
Transplantation
Sandra K. Call,1,2 Kimberly A. Kasow,3,4 Raymond Barfield,3,4 Renee Madden,3,4
Wing Leung,3,4 Edwin Horwitz,3,4 Paul Woodard,3,4 John C. Panetta,5 Sharyn Baker,5
Rupert Handgretinger,3,4 John Rodman,1,* Gregory A. Hale3
Rabbit antithymocyte globulin (rATG; Thymoglobulin) is currently used to prevent or treat graft-versus-host
disease (GVHD) during hematopoietic stem cell transplantation (HSCT). The dose and schedule of rATG as
part of the preparative regimen for unrelated donor (URD) bone marrow transplantation (BMT) have not
been optimized in pediatric patients. We conducted a prospective study of 13 pediatric patients with hemato-
logic malignancies undergoing URD BMTat St. Jude Children’s Research Hospital from October 2003 to March
2005, to determine the pharmacokinetics and toxicities of active and total rATG. The conditioning regimen
comprised total body irradiation (TBI), thiotepa, and cyclophosphamide (Cy); cyclosporine (CsA) and metho-
trexate (MTX) were administered as GVHD prophylaxis. Patients received a total dose of 10 mg/kg rATG, and
serial blood samples were assayed for total rATG by enzyme linked immunosorbent assay (ELISA) and active
rATGby florescein activated cell sorting (FACS). We found thatourweight-based dosing regimen for rATG was
effective and well tolerated by patients. The half-lives of total and active rATG were comparable to those from
previous studies, and despite high doses our patients had low maximum concentrations of active and total
rATG. There were no occurrences of grade iii-iv GVHD even in patients having low peak rATG levels, and
the overall incidence of grade II GVHD was only 15%. None of the patients had serious infections following
transplantation. These data support the use of a 10 mg/kg dose of rATG in children with hematologic malignan-
cies because it can be administered without increasing the riskof graft rejection, or serious infection in pediatric
patients with a low rate of GVHD. These conclusions may not apply to patients with nonmalignant disorders.
Biol Blood Marrow Transplant 15: 274-278 (2009) 2009 American Society for Blood and Marrow Transplantation
KEY WORDS: Thymoglobulin, Hematopoietic stem cell transplantation, Bone marrow transplantation,
Pediatrics, Pharmacokinetics, Rabbit antithymocyte globulin (rATG), Graft-versus-host disease (GVHD)INTRODUCTION
Rabbit antithymocyte globulin (rATG), a poly-
clonal antibody that targets human T lymphocytes, is
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doi:10.1016/j.bbmt.2008.11.027274currently approved for treatment of acute rejection in
renal transplant recipients. Because of its activity
against T cells, it is frequently used for hematopoietic
stem cell transplantation centers to prevent [1-7] or
treat [8,9] graft-versus-host disease (GVHD) and to
improve engraftment of donor stem cells during hema-
topoietic transplantation [1-7].
Currently, 2 polyclonal antibodies—Thymoglobu-
lin (rATG) and Atgam (equine ATG, eATG)—are
commercially available in the United States and differ
in their biologic activities. Compared with eATG,
rATG shows activity at lower doses (15 mg/kg versus
1.5 mg/kg, respectively). rATG also has a considerably
longer half-life (5.7 versus 30 days, package insert) and
higher specificity for human T lymphocytes than
eATG, thereby favoring its use for hematopoietic
stem cell transplant (HSCT). Our institution chose to
use rATG because of its longer half-life and activity
at lower doses.
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rATG in adults [2,10-12] and only 1 study [13] in chil-
dren. The optimal dose and schedule of rATG as part
of the preparative regimen for bone marrow transplan-
tation (BMT) have not yet been defined. High or low
doses of rATG can alter the risk of GVHD, graft rejec-
tion, or infectious complications [1,11,13]. At this time,
low and high doses have not been firmly established.
To evaluate the pharmacokinetics of active and to-
tal rATG and toxicities associated with the dosing reg-
imen, we performed a prospective clinical trial in
children who underwent an unrelated donor (URD)
BMT for hematologic malignancies at St. Jude Child-
ren’s Research Hospital from October 2003 to March
2005. We assayed total and active rATG serum con-
centrations at multiple defined time points and as-
sessed the effectivity and tolerance of the dose and
schedule of rATG in this pediatric group.
MATERIALS AND METHODS
Patients
Thirteen pediatric patients undergoing an URD
BMT for hematologic malignancy were enrolled in a pro-
spective clinical trial at St. Jude Children’s Research Hos-
pital from October 2003 to March 2005. All patients
received non-T cell-depleted bone marrow grafts from
unrelated donors. High-resolution HLA typing was per-
formed for the loci A, B, C, DR, and DQ. Donors were
considered acceptable if they matched the recipient at
the allele level at 7 of 8 or 8 of 8 loci. The trial was ap-
proved by the St. Jude institutional review board, and
all research participants gave informed consent and assent
(as appropriate) for participation.
Conditioning Regimen
The conditioning regimen comprised 12 Gy total
body irradiation (TBI; fractionated into 8 doses on
days –8 to –5), thiotepa (5 mg/kg/dose for 2 doses
on day –4), and cyclophosphamide (Cy; 60 mg/kg/
dose on days –3 and –2). GVHD prophylaxis consisted
of cyclosporine initiated on day 22 at 2.5 mg/kg/dose
intravenously (i.v.) every 12 hours and adjusted to
maintain trough concentrations between 170 and 250
ng/mL by the enzyme multiplied immunoassay tech-
nique (EMIT), and methotrexate i.v. (MTX; 15 mg/
m2/dose on day 11; 10 mg/m2/dose on days 13, 16,
and 111). rATG was administered intravenously via
a central venous access device. All patients received
1 mg/kg rATG on day –4 over 1 hour and 3 mg/kg
on days –3, –2, and –1 (total dose 10 mg/kg) over 6
hours each day. To minimize side effects, all patients
received premedications (methylprednisolone, diph-
enhydramine, and acetaminophen) before each
rATG dose and a continuous i.v. infusion of hydrocor-
tisone (5 mg/kg) during rATG infusion.Collection of Information on Adverse Events
Information on adverse events was collected pro-
spectively and scored according to the common toxic-
ity criteria (CTC) of the National Cancer Institute
(NCI) Version 2 (http://ctep.cancer.gov/reporting/
ctc_archive.html) and reported at least annually as
appropriate to institutional committees and the Food
and Drug Administration. Adverse events were
assigned by the treating physician or principal investi-
gator. Relationship to treatment and classification of
event (expected or unexpected) for grade III and IV
adverse events were detailed. Acute and chronic
GVHD (aGVHD, cGVHD) were graded according
to established criteria [14]. To assure patient safety
and data validity and integrity, an independent Data
Safety Monitoring Board (DSMB) at St. Jude con-
ducted regular reviews of the study’s clinical and
safety-related data.
Measurement of Total and Active rATG
Blood samples (2-3 mL) were obtained at baseline
(before administering the test dose of rATG), before
each 3 mg/kg dose, and before reinfusion of stem cells.
After the transplant, blood samples were obtained on
days 11, 13, 15, and 17, and at weeks 1, 2, 4, 8, 16,
and 24. Serum was separated within 2 hours of blood
collection and stored at –70C (Translational Trials
Unit Core Pharmacology Laboratory, St. Jude Child-
ren’s Research Hospital) until they were shipped on
dry ice to Genzyme (Cambridge, MA) for processing.
Total and active plasma rATG were determined by
Genzyme by the method of Regan et al. [12]. Total
plasma rATG was determined by enzyme-linked
immunosorbent assay (ELISA) (limit of quantification
3.9 mg/mL) and active plasma rATG by FACS (limit of
quantification 0.2 mg/mL).
Pharmacokinetic Methods
We used a 2-compartment pharmacokinetic model
with first-order elimination (ADVAN 3 subroutine in
NONMEM version V, double precision, level 1.1
using the first-order conditional estimation [FOCE]
method with INTERACTION] [15]) to describe total
and active rATG. The POSTHOC option was used to
estimate individual parameters. Pharmacokinetic
parameters estimated by the model were systemic
clearance (CL), volume of the central compartment
(V), and intercompartmental rate constants (k12, k21).
Intersubject variability was modeled with an exponen-
tial model.
RESULTS
Of the 13 patients enrolled, 11 were male. The
median age at BMT was 10 years (range: 2-16 years).
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Patient Diagnosis Age(years) Weight(kg) Disease Statusat Transplant Days toANC >500/mm3
Days toPlatelets >20 103/mm3
without Transfusion x7 days
001 AML 12 40.8 CR2 17 49
002 JCML 2 13.4 PD 22 32
003 AML 16 60.4 CR1 23 48
004 AML 10 38.7 CR1 23 38
005 ALL 3 14.5 CR3 16 28
006 CML 10 36.7 CP1 19 27
007 CML 16 86.6 CP1 19 26
008 MDS 12 40 SD 19 33
009 CML 8 29.3 CP2 16 18
010 JCML 3 14.1 CR1 21 29
011 ALL 10 34.9 CR3 17 25
012 AML 2 11.1 CR1 17 34
013 ALL 14 48.5 CR2 15 25
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; JCML, juvenile chronic myelogenous leukemia; CML, chronic myelog-
enous leukemia; MDS, myelodysplastic syndrome; CR, complete remission; CP, chronic phase; PD, progressive disease; SD, stable disease; ANC, absolute
neutrophil count.The median weight was 36.7 kg (range: 11.1-86.6 kg).
Three patients had chronic myelogenous leukemia
(CML; 2 in first chronic phase and 1 in the second
chronic phase), 3 had acute lymphoblastic leukemia
(ALL; 1 CR1 and 2 CR3), 4 had acute myelogenous
leukemia (AML; 3 CR1 and 1 CR2), 2 had juvenile
CML (JCML; 1 CR1 and 1 progressive disease
[PD]), and 1 had myelodysplastic syndrome (MDS;
stable disease) (Table 1). Sex, diagnosis, and age did
not affect the results (data not shown).
We observed a biphasic elimination of total and ac-
tive rATG in our patients (Figure 1). Mean CL for the
population for total and active rATG was 198 and 4530
mL/day, respectively. The intersubject variability (co-
efficient of variation [CV%]) in the CL for total and
active rATG were 47% and 61%, respectively. When
accounting for the positive relation between CL and
weight (kg) (Figure 2), intersubject variability (CV%)
significantly decreased (P\ .0001) to 37% and 50%,
respectively. On the basis of post hoc estimates, the
median beta half-lives for total and active rATG
were 27.3 days (range: 25.7-30.4 days) and 12.5 days
(range: 5.8-22.4 days), respectively. In addition, the
median actual Cmax values were 57.7 (range: 23.7-
80.7) and 4.0 (range: 1.6-8.0) mg/mL, respectively.
Total rATG was measurable in all patients until
week 4 and in 11 of 13 patients until week 8. Mean total
rATG on day 0 was 53mg/mL (range: 23.7-80.7mg/mL)
and on day 28 was 15.9mg/mL (range: 5.1-20.6mg/mL).
Active rATG was measurable in all patients through
week 2, 10 patients at week 4, and undetectable (\0.2
mg/mL) in 7 patients at week 8. Mean active rATG on
day 0 was 4 mg/mL (range: 1.6-8.0) and on day 28 was
1.13 mg/mL (range\0.2-4.64). Corresponding median
concentrations for total and active rATG showed simi-
lar elimination curves (data not shown).
All patients achieved neutrophil engraftment at
a median of day 119 (range: 15-23 days) and platelet
engraftment at a median of day 132 (range: 15-34
days). There were no episodes of grade iii or ivGVHD; 2 patients developed grade 2 GVHD. There
were no grade iii or iv nonhematologic serious adverse
events, no grade iii or iv serious adverse events related
to rATG administration, and no serious infections.
One of the patients developed cGVHD (overall inci-
dence of 7.6%). Patients were tested weekly by poly-
merase chain reaction (PCR) in peripheral blood for
cytomegalovirus (CMV), adenovirus (ADV), and
Epstein Barr Virus (EBV). All detectable copy num-
bers for CMV were indications for treatment with
ganciclovir or foscarnet. EBV was treated with rituxi-
mab if copy numbers exceeded 2000 copies/mg total
cellular DNA. Three patients reactivated CMV in
the first 45 days posttransplant. One patient developed
a positive PCR for ADV, and there were 6 episodes of
positive PCR for EBV all with copy numbers less than
our threshold for treatment.
DISCUSSION
Our weight-based dosing regimen (total dose 10
mg/kg) of rATG was effective and well tolerated by
pediatric patients undergoing an URD BMT for
hematologic malignancy. There was no grade 4 non-
hematologic toxicity, the overall incidence of aGVHD
(maximum grade II) was 15%, and there were no
occurrences of grade iii-iv GVHD, despite 11 of 13 pa-
tients having peak total rATG levels\70 mg/mL on
day 0. Also, there were no serious infections in any
patient after transplant. Only 1 of 13 patients relapsed:
his day 0 concentration of rATG was\70 mg/mL, and
he had an active rATG of .1 mg/mL for 2 weeks
(average follow-up 3 years) [2,11].
We observed 2 phases of clearance for both total
and active rATG in our patients, which is consistent
with the results of Waller et al. [11] and Regan et al.
[12]. Although the dose and schedule given to our
patients were different from those of previously pub-
lished studies (Waller et al. [11], 6 mg/kg; Guttmann
et al. [10], 7 mg/kg; Seidel et al. [13], dose range
Biol Blood Marrow Transplant 15:274-278, 2009 277rATG Pharmacokinetics in Pediatric BMT PatientsFigure 1. Total rATG (top) and active rATG (bottom) versus time. Squares represent data and the solid curve represents the population average model
fitted curve. LOQ: limit of quantification (3.9 mg/mL for total ATG and 0.2 mg/mL for active ATG). Because the assay only indicated that a level was below
the LOQ rather than assigning a specific value to it, we randomly assigned it a level below the LOQ to improve the visual interpretation of the results.
Time line represents time from first rATG dose. No patient had measurable rATG concentrations prior to the first dose.7.5-40 mg/kg), the half-lives for total and active
rATG were similar to those found in previous adult
studies [2,10-12]. Conversely, despite receiving
higher doses, the peak total concentrations of rATG
for our patients were 67% and 28% lower than in
studies by Waller et al. [11] and Guttmann et al.
[10], respectively. In the only other pediatric study
Seidel and colleagues [13] reported concentrations
of active rATG approximately 60% higher than our
median peak concentration of 4 mg/mL at a dose
25% lower than the dose used in our study. These
differences might be attributed to differences in sam-
pling times between their study and ours. Remberger
et al. [2] have suggested that peak concentrations of
total rATG \70 mg/mL before and 1 week after
BMT increases patient’s risk of developing grade
II–IV aGVHD. In our study, only 2 patients had total
rATG concentrations of .70 mg/mL at day 0 and
neither developed GVHD. On the other hand, only2 of 11 patients who had day 0 concentrations
\70 mg/mL developed grade II GvHD (overall inci-
dence 15%).
Waller et al. [11] have suggested that\1 mg/mL of
active rATG is subtherapeutic. The 2 patients who de-
veloped aGVHD had\1 mg/mL active rATG concen-
trations by week 2. The concentrations of active rATG
were measurable to day 28 in 10 patients who had low
incidence of GVHD. This low incidence in our pa-
tients might have been because active rATG persisted
in the serum; however, inhibition of T cell stimulation
by phytohemagglutinin (PHA) in vitro by rATG (as
described by Remberger et al. [5]) was not performed
as samples were not assayed in real time and thus
T cell function could not be assessed.
The primary limitation of our study is the low
patient numbers, yet we were able to describe the
pharmacokinetics of rATG in pediatric patients in
a prospective study. These data support a hypothesis
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ministered without increasing the risk of GVHD, graft
rejection, or serious infection in pediatric patients with
heamtologic malignancies. The definition of low- or
high-dose rATG remains to be determined in the
BMT population, although an attempt has been made
by Remberger and colleagues [16] to delineate differ-
ences in outcome in patients who received different
doses of rATG. Using retrospective data from 1989-
2003, they evaluated BMT outcomes from 4 different
doses of rATG (4 mg/kg, 6 mg/kg, 8 mg/kg, and 10
mg/kg). They found a higher incidence of infections
in the 10 mg/kg patients, who received transplants in
the 1990s. Our data did not show an increased risk of
infections in our patients; this may be because of differ-
ences in infection prophylaxis over the past 18 years.
Whether total thymoglobulin or active thymoglobulin
concentrations are more predictive of GVHD, engraft-
ment or risk of relapse also remain to be answered.
Figure 2. Total rATG clearance (top) and active rATG clearance (bot-
tom) versus weight.ACKNOWLEGMENTS
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